restrict the use of Rezulin (troglitazone) for diabetes

The FDA will further restrict the use of Rezulin (troglitazone) for diabetes.

There continue to be deaths due to hepatic failure...despite recommendations for more frequent monitoring.

Very few Rezulin patients get regular liver function tests.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote